IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Assimastion of

STEFAN KNACKMUSS ET AL

U.S. Serial No. 10/574,961

Group Art Unit 1648

Filed: July 5, 2006

Examiner: A. Boesen

SINGLE CHAIN ANTIBODIES AGAINST 37 KDA/67 KDA LAMININ RECEPTOR AS TOOLS FOR THE DIAGNOSIS AND THERAPY OF PRION DISEASES AND CANCER, PRODUCTION AND USE THEREOF

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Transmitted herewith is $\frac{1}{2}$ an $\frac{1}{2}$ and $\frac{1}{2}$ are sponse in the above-identified application.

X No additional fee is required.
An additional fee is required as calculated below -

	Claims Remaining After	Highest No. Previously	Present	Small En	<u>tity</u> Addnl.		Than A Entity Addnl.
	Amendment	Paid For	Extra	Rate	Fee	Rate	Fee
Total Indep First	Presentation of	Minus * Minus * Mul Dep Claim		x \$ 25 \$_ x \$105 \$_ x \$185 \$		x\$ 50 \$ x\$210 \$ x\$370 \$	5
	Total A	dditional Fee		<u>\$</u>			5

- * The "Highest Number Previously Paid For" (Total or Independent) is the highest number of claims filed originally or highest number found from equivalent box of a prior amendment.
- X This response is being filed within the period for response.
- Applicant(s) hereby petition for an extension from the date
 of the Examiner's Action as follows:

First-Month Extension	\$ 60.00	/	\$	120.00
Second-Month Extension	\$ 230.00	/	\$	460.00
 Third-Month Extension	\$ 525.00	/	\$1	.050.00

____ Small entity status of this application has been established.

A Check in the amount of \$\(\frac{0.00}{0.00}\) is attached hereto. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-3690 of the undersigned attorney. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: November 29, 2007 (703) 684-6885

Mary J. Breiner, Reg. No. 33,161

"PATENT APPLICATION"

6713/PCT/tat

NOV 29 2007 LE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of

STEFAN KNACKMUSS ET AL

U.S. Serial No. 10/574,961

Group Art Unit 1648

Filed: July 5, 2006

A. Boesen, Examiner

SINGLE CHAIN ANTIBODIES AGAINST 37 KDA/67 KDA LAMININ RECEPTOR AS TOOLS FOR THE DIAGNOSIS AND THERAPY OF PRION DISEASES AND CANCER, PRODUCTION AND USE THEREOF

> Alexandria, Virginia November 29, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RESPONSE

Dear Sir:

This is in response to the official action mailed November 2, 2007.

The Examiner has required restriction under 35
U.S.C. §121 and 372 as follows: Group I, i.e, claims 1 and
2, drawn to a single-chain antibody against LRP/LR,
comprising the amino acid sequence SEQ ID NO: 2; Group II,
i.e., claims 5 and 6, drawn to a single chain antibody
against LRP/LR, comprising the amino acid SEQ ID NO: 4; or
Group III, i.e., claims 3, 4, 7, 8, 11 and 14-23, drawn to a
cDNA, which comprises the nucleotide sequence SEQ ID NO: 3.

6713/USSN 10/574,961 Group Art Unit 1648

The Examiner advises that claims 9, 10, 12, 13 and 24-36 link the inventions of Groups I and II and that the restriction requirement between the linked inventions is subject to nonallowance of the linking claims. Upon indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and claim(s) rejoined.

Applicants hereby elect to prosecute the claims of Group I, claims 1 and 2, drawn to a single-chain antibody against LRP/LR, comprising the amino acid sequence SEQ ID NO: 2. Applicants reserve the right to file a divisional application(s) containing claims drawn to the non-elected subject matter.

Favorable consideration of the application is requested.

Respectfully submitted,
STEFAN KNACKMUSS ET AL

Rν

Mary J. Breiner, Attorney Registration No. 33,161 BREINER & BREINER, L.L.C.

P.O. Box 320160

Alexandria, Virginia 22320-0160

Telephone: (703) 684-6885